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Periodic resurgences of COVID-19 in the coming years can be expected,
while public health interventions may be able to reduce their intensity. We
used a transmission model to assess how the use of booster doses and
non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution
might influence future transmission waves. We find that incidence is likely
to increase as NPIs relax, with a second seasonally driven surge expected
in autumn 2022. However, booster doses can greatly reduce the intensity
of both waves and reduce cumulative deaths by 20% between 7 January
2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining
boosters and NPIs results in a 30% decrease in cumulative deaths, with
potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides
similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs
and boosters). If novel variants with increased transmissibility or immune
escape emerge, deaths will be higher, but vaccination and NPIs are expected
to remain effective tools to decrease both cumulative and peak health system
burden, providing proportionally similar relative impacts.

1. Introduction
COVID-19 has caused catastrophic loss of life and health system strain in the
United States [1]. Since the US epidemic first began in early 2020, multiple
transmission waves have occurred, triggered by changes in social distancing
and circulating variants. In response, the US government enacted widespread
non-pharmaceutical interventions (NPIs) to slow epidemic spread. Over time,
these measures relaxed in favour of more targeted approaches, particularly as
vaccination became more available.
As of June 2022, three types of highly effective COVID-19 vaccines are available in the USA [2], two of which have been authorized for emergency use
in children six months and above [3]. However, vaccine effectiveness has
decreased over time, partly due to waning efficacy and partly due to the emergence of novel variants against which vaccines are less effective [4]. As a result,
booster doses have been recommended to maintain efficacy [2].
The US epidemic beginning in early 2020 was triggered by the Wuhan
variant, with the winter 2020 surge driven by the Delta variant, which was
© 2022 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
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Figure 1. Transmission model. Individuals are classified as susceptible (S), latently infected (E), symptomatic (I), asymptomatic (A), hospitalized (H), recovered (R) or
deceased (D). Individuals are also classified by their vaccination status as either unvaccinated (blue), vaccinated with two doses (yellow), or vaccinated and boosted
(green). Individuals who are infected with SARS-CoV-2 wane into their own infection class.

more infectious and severe than prior dominant variants
[5,6]. In late 2021, the Omicron variant began to predominate.
The Omicron variant seems to be more transmissible but less
severe than prior variants [6,7]. Moreover, vaccine efficacy
against both infection and severe disease appears to be
lower against the Omicron variant [8]. However, booster
doses may at least temporarily increase vaccine efficacy
against circulating variants [9].
As circulation continues, ongoing SARS-CoV-2 evolution
might allow immune escape to occur, influencing the intensity of follow-up waves [10]. Additional NPIs might be
rolled out in response to subsequent surges in cases, influencing the severity of future transmission waves. We used a
transmission model to evaluate how booster doses and
resuming NPIs amid ongoing pathogen evolution might
influence the severity of SARS-CoV-2 transmission.

2. Methods
Our transmission model extends classic compartmental
susceptible–exposed–infected–recovered (SEIR) epidemiological
models to incorporate additional features relevant to the transmission dynamics of SARS-CoV-2. Our SEIR-like model
includes seven compartments (figure 1). Initially, many individuals are susceptible to infection (S). Upon exposure, they enter a
latent period (E), during which they cannot transmit. They can
then develop asymptomatic infection (entering the A class) or
symptomatic infection (entering the I class). We assume that all
asymptomatic individuals will recover (R). Those with symptomatic infections can either recover (entering the R class) or
require hospitalization (entering the H class). Some of those

hospitalized will die (entering the deceased class D), and the
rest will recover (entering the R class). After immunity wanes,
individuals in the R class return to their S class, depending on
vaccine status. The model was also stratified by age (less than
20 years, 20–64 years and greater than or equal to 65 years)
and risk of acquiring infection (high versus low).
Vaccination was implemented by adding a daily rate of
vaccination and additional compartments for vaccinated individuals, which mirror the compartments in the base model: SV, EV,
AV, IV, RV, HV and DV. For simplicity, we assume that individuals
in the S or R classes can be vaccinated but individuals in
the other compartments will not be. Following vaccination,
susceptible individuals S move into the susceptible vaccinated
compartment SV, and all recovered individuals move into the
recovered vaccinated compartment RV. We used coverage estimates from 6 January 2022 to estimate the baseline prevalence
of vaccination [1]. We assume that all adults who intend to be
vaccinated have already done so and that future vaccines will
be allocated to children or will be booster doses, with peak
child vaccine coverage being reached by late October 2022,
consistent with current vaccine rates [1]. Baseline immunity
and initial age distribution of infections were estimated using
seroprevalence data [11]. Primary series vaccination was modelled as reducing the risk of severe disease by 70% (50%
reduction in infection and 40% reduction in hospitalization
given infection) [12] and 90% if booster doses are used (50%
reduction in infection and 80% reduction in severe disease
given infection) [9]. In the absence of any new vaccine products,
we assume that all boosted individuals remain current on their
boosted status and that any further vaccinations do not increase
efficacy further such that only one boosted class is sufficient.
We also consider potential impacts if a variant-specific booster becomes available in autumn 2022 (electronic supplementary
material, figure S2). For this analysis, we added a third vaccine
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Figure 2. Daily deaths (top row) and infections (bottom row) from SARS-CoV-2 waves as a function of immune escape, booster vaccine strategy and social
distancing.

class to the model, with vaccine efficacy against infection being
increased to 90% for individuals with the variant-adapted booster, consistent with initial efficacy data for both mRNA vaccines
[13]. Vaccine efficacy against severe disease was assumed to be
similar with first and second boosters, such that the combined
effectiveness against hospitalization with an adapted booster
was 98%. All booster doses administered after 1 September,
2022 were assumed to be with the variant-adapted booster.
To parametrize this model, we set parameter values where
known. For uncertain parameters, we selected model parameters
based on both reasonable values from the literature and the ability of the model to reproduce Omicron dynamics. Model
parameters are shown in the electronic supplementary material,
table S1. As the duration of immunity is uncertain, we also conducted a sensitivity analysis with a shorter duration of immunity
(90 days).
We assume that relaxation of NPIs began in March 2022,
reaching baseline [14] (i.e. pre-pandemic) levels by 7 July 2022.
This timeline is consistent with announced policy decisions in
multiple US states [15]. We consider a scenario where these
NPIs remained at their relaxed level as the seasonal transmission
rate increases. We then explore whether a temporary increase in
social distancing to levels observed during Omicron might
impact risk if implemented in autumn 2022.
To explore impacts in the context of ongoing pathogen
evolution, we first use model parameters consistent with the
circulating Omicron variant (electronic supplementary material,
table S1) for 1 year, beginning 7 January 2022. Our seasonal

transmission model implies that transmission will increase in
the autumn, even if no novel variants emerge. We then consider
how increasing transmissibility might impact model dynamics.
For this scenario, we assume that the novel variant begins to
emerge in the autumn, coincident with increases in the seasonal
transmission rate and that the maximum seasonal beta term is
increased by 20–50% at the start of the autumn. The circulation
of this variant thus has the potential to drive a surge in infections
beyond the effect that increases in the seasonal transmission rate
can have on driving an autumn wave. We also consider how
changes in the new variant’s ability to escape immunity might
impact dynamics by increasing the rate of waning immunity
by 50%, consistent with immune escape.

3. Results
Our model closely matches peak daily deaths and hospitalization rates observed for the Omicron wave in January and
February 2022, with peak daily deaths around 2200 day−1.
In our model, incidence is predicted to rebound in June
2022 as NPIs relax and natural immunity wanes (figure 2).
This rebound is expected to be largely driven by relaxing
NPIs, with waning immunity playing a secondary role.
Specifically, deaths were predicted to increase from a low of
520 to 1064 day−1 after 180 days (a 104% increase). Twentyfive per cent of this increase was attributable to waning
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4. Discussion
Our model predicts both a mid-year peak (driven by relaxing
NPIs) and an autumn resurgence (driven by seasonal
increases in the transmission rate). However, public health
interventions can substantially impact these dynamics; combining boosters and NPIs could reduce deaths by up to
34%. If a novel variant emerges that escapes immunity,
deaths could increase, but both interventions remain beneficial. While combining booster doses and NPIs reduce
morbidity and mortality, we find that targeting NPI use to
high transmission periods has similar benefits to indefinite
NPIs. Thus, widespread use of booster doses can allow
NPIs to remain more relaxed with relative safety.
While vaccines may not be as effective against infection
with novel variants, evidence to date suggests that existing
vaccines are likely to provide good protection against more
severe disease, even for genetically distant variants like Omicron [16], particularly if booster doses are used [17]. New
vaccine formulations targeted to circulating variants have
the potential to improve efficacy. However, in our model,
the impact of adapted boosting was modest. This pattern
probably occurred because booster doses were not administered quickly enough to curtail an autumn transmission
surge. We predicted that 30% of older adults, 27% of adults
and 17% of children would be vaccinated with a variantadapted booster by January 2023. Faster roll-out rates might
enhance impacts beyond what we have modelled.
These findings are meant to be understood qualitatively in
terms of the overall pattern of risk rather than predicting a precise level of future burden; real disease risk is likely to be lower
than we have modelled for a few reasons. For example, while
we predict a relatively high level of ongoing deaths, fatality
from COVID-19 may be lower due to both incomplete
waning of immunity and improved treatment. We have used
simple assumptions in this model, with an average immunity
level of seven months followed by complete waning to baseline risk by vaccine group. However, immunity may accrue
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allowed to relax. For this reason, daily deaths are higher if a
novel variant with increased transmissibility emerges and
NPIs are sustained indefinitely (electronic supplementary
material, figure S1).
As a sensitivity analysis, we considered implications if
natural infection provides additional immunity equivalent to
receiving either (i) a two-dose series of vaccine or (ii) a booster
dose (electronic supplementary material, figure S3). In this
sensitivity analysis, the patterns seen in the overall results
were similar, but deaths and infections were lower. For
example, combining NPIs and booster doses reduced deaths
by 25% without immune escape for the hybrid immunity
extension compared with 30% in the base model. However,
overall deaths between January 2022 and January 2023 were
237 000 with hybrid immunity, boosters and NPIs compared
with 317 000 for the same scenario without hybrid immunity
(electronic supplementary material, table S3 and figure S3).
We also considered implications if the duration of immunity
to COVID-19 lasted three months rather than the seven months
we used for our main model simulations. While peak deaths
and were higher in this model and the autumn surge was
more intense, the impact of boosting and reintroducing NPIs
was similar (electronic supplementary material, figure S6).

royalsocietypublishing.org/journal/rsif

immunity alone, with the remainder being due to relaxing
NPIs and the interaction between NPI relaxation and
waning immunity (electronic supplementary material,
figure S1 and text). Booster doses can influence the intensity
of this spring/summer resurgence. Daily deaths at the end of
the summer wave (on 21 July 2022) were 18% lower if
boosters were used.
Additionally, seasonal changes in transmission are
expected to produce a new transmission wave in autumn
2022. The severity of this autumn transmission wave will
depend on the implementation and uptake of public health
interventions over the coming months as well as ongoing variant evolution. In the absence of a new immune variant
emerging that has increased transmissibility, high uptake of
booster doses could reduce cumulative deaths between
March 2022 and January 2023 by 20% while also reducing
the intensity of the autumn surge. Reintroducing NPIs as the
seasonal transmission rate begins to increase can also further
reduce risk and could effectively halt an autumn resurgence
if immune escape does not occur or if its level is low
(figure 2). Combining booster doses with NPIs could reduce
cumulative deaths by up to 30% compared with a scenario
without booster doses or NPIs. Increased transmissibility
could increase peak deaths, but the per cent reduction in
deaths achievable through booster vaccination is similar (the
fraction of preventable deaths is 20% with 50% immune
escape and increases to 27% with combined boosters and
NPIs). Similarly, immune escape could lead to increased
deaths (electronic supplementary material, figure S4), but
booster vaccination remains beneficial. Roll-out of variantspecific boosters that have increased effectiveness against
infection could be beneficial, but predicted impacts are small
due to the expected constant roll-out rates of these variantspecific boosters (e.g. we do not model an aggressive vaccine
campaign in autumn 2022). Specifically, if variant-adapted
booster vaccination continues at the roll-out rates observed
in January 2022, combined boosting and NPIs could reduce
deaths by 34% without any increases in transmissibility or
30% with increased transmissibility (electronic supplementary
material, table S3).
In addition to reducing deaths, NPIs also reduced overall
infections (figure 2). Without immune escape, NPIs alone
could reduce infections by 16% between 21 July 2022 and 6
January 2023. If immune escape occurs, the overall impact of
NPIs is reduced, with similar NPIs reducing infections by
11% during the autumn. By contrast, standard booster doses
do not impact overall infection rates. Adapted booster doses
could reduce infection rates in future waves, but are unlikely
to do so substantially during the autumn 2022 wave. We
also found that the benefit of NPIs is specific to high transmission periods—when booster vaccines are used, allowing
NPIs to relax during the summer and reintroducing in the
autumn provides similar benefits to indefinite NPIs (307 000
deaths with indefinite NPIs compared with 317 000 with
targeted NPIs).
While reintroducing NPIs during the autumn was beneficial, our model also revealed that relaxing NPIs during the
summer was beneficial for follow-up transmission waves
because it allowed for population immunity to accrue, reducing
the number of people who were simultaneously susceptible to
infection. When NPIs are sustained, the overall number of susceptible individuals is about 30% higher at the start of the
autumn surge compared with the scenario where NPIs are
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more gradually over repeated infections and reach a higher
level, as has been shown for other pathogens [18] and preliminary data show might also be true for SARS-CoV-2 [19]. Our
sensitivity analysis suggests that this tendency would probably decrease deaths, but would not impact the overall
utility of booster doses and NPIs.
In conclusion, our simulations suggest that resurgences in
COVID-19 cases are likely both in the summer, as NPIs continue to relax, and in the autumn, as seasonal factors push
the transmission rate higher. However, widespread use of booster doses can make a substantial impact on the ongoing public
health burden, even as novel variants continue to emerge. Reestablishing NPIs can also reduce the impact of future transmission waves. While ongoing viral evolution that results in
increased transmissibility may increase cases and deaths,
both vaccines and NPIs remain beneficial to reduce the public
health burden of future surges of COVID-19.

